aTyr Pharma Reports Reduced Net Loss of $10.3 Million in Q2 2026

aTyr Pharma, Inc. reported its financial results for the second quarter of 2026, revealing a consolidated net loss of $10.3 million, a decrease from a net loss of $19.5 million in the same period of 2025. For the first half of 2026, the company recorded a net loss of $21.1 million, down from $34.4 million in the prior year. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $6.7 million in Q2 2026 from $15.4 million in Q2 2025, primarily due to the completion of the EFZO-FIT study for efzofitimod, a key therapeutic candidate.

Total operating expenses for the second quarter of 2026 were $10.9 million, compared to $20.3 million in the same quarter of 2025. The decrease in expenses reflects a strategic shift in the company's focus and a reduction in costs associated with the efzofitimod program. General and administrative expenses also saw a decline, totaling $4.1 million in Q2 2026, down from $4.9 million in Q2 2025. The company’s accumulated deficit as of June 30, 2026, stood at $627.3 million, indicating ongoing financial challenges as it continues to seek funding for its operations.

In terms of operational developments, aTyr Pharma has undergone significant organizational changes, including a corporate restructuring plan approved on August 7, 2026, which aims to streamline operations and conserve capital. This plan includes a workforce reduction of approximately 60%, bringing the total number of employees down to 20. The company anticipates that this restructuring will reduce annual operating expenses by about $13 million starting in Q4 2026. Additionally, aTyr Pharma has reverted to holding global rights for efzofitimod after the termination of its collaboration agreement with Kyorin Pharmaceutical Co., Ltd. in May 2026.

The company’s cash and cash equivalents increased to $16.2 million as of June 30, 2026, up from $10.7 million at the end of 2025. However, aTyr Pharma did not utilize its at-the-market offering program during the first half of 2026, which may limit its ability to raise additional capital in the near term. The company believes its current cash reserves will be sufficient to meet its material cash requirements for at least one year from the filing date of the quarterly report. Looking ahead, aTyr Pharma plans to initiate a new Phase 3 study for efzofitimod in pulmonary sarcoidosis, contingent on securing additional funding and regulatory approvals.